阿魏酸哌嗪聯合厄貝沙坦在糖尿病腎病中的應用效果及對腎功能的影響

【摘要】 目的：探究阿魏酸哌嗪聯合厄貝沙坦在糖尿病腎病中的療效及對腎功能的影響。方法：將2019年6月—2022年2月景德鎮市第二人民醫院的82例糖尿病腎病患者根據隨機數字表法分為對照組41例和觀察組41例。對照組采用厄貝沙坦進行治療，觀察組則采用阿魏酸哌嗪聯合厄貝沙坦進行治療，以12周為一個比較期。比較兩組治療總有效率、治療前后主腎動脈血流指標[收縮期最大流速（Vps）、舒張末期血流速度（Ved）及腎阻力指數（RI）]、腎功能指標[血肌酐（Cr）、24 h尿蛋白、血清尿素氮（BUN）、尿白蛋白排泄率（UAER）及腎小球濾過率（GFR）]。結果：觀察組治療總有效率為90.24%，顯著高于對照組的65.85%，差異有統計學意義（Plt;0.05）。治療前兩組主腎動脈血流指標、腎功能指標比較，差異均無統計學意義（Pgt;0.05）。治療12周后兩組主腎動脈Vps、Ved均較治療前提高，觀察組上述指標均顯著高于對照組，兩組RI均較治療前降低，且觀察組RI低于對照組；兩組Cr、24 h尿蛋白、BUN、UAER較治療前均顯著降低，且觀察組均顯著低于對照組，兩組GFR均較治療前升高，且觀察組高于對照組，差異均有統計學意義（Plt;0.05）。結論：阿魏酸哌嗪聯合厄貝沙坦在糖尿病腎病中的療效較好，且可有效改善腎功能，在糖尿病腎病患者中的應用價值相對較高。

【關鍵詞】 阿魏酸哌嗪 厄貝沙坦 糖尿病腎病 腎功能

Application Effect of Piperazine Ferulate Combined with Irbesartan in the Patients with Diabetic Nephropathy and Influence for Kidney Function/YU Fang， JIANG Xin’ai， WU Yali， XU Xianhai， PENG Lijing. //Medical Innovation of China， 2023， 20（31）： 0-018

[Abstract] Objective： To investigate the effect of Piperazine Ferulate combined with Irbesartan in the patients with diabetic nephropathy and influence for kidney function. Method： A total of 82 patients with diabetic nephropathy in the Second People's Hospital of Jingdezhen from June 2019 to February 2022 were divided into the control group with 41 cases and the observation group with 41 cases according to the random number table method. The control group were treated with Irbesartan， the observation group were treated with Piperazine Ferulate combined with Irbesartan. The total effective rates， main renal artery blood flow index [velocity peak systolic （Vps）， velocity end diastolic （Ved）， renal resistance index （RI）]， renal function indexes [creatinine （Cr）， 24 h urine protein， blood urea nitrogen （BUN）， urinary albumin excretion rate （UAER） and glomeruar filtration rate （GFR）] before and after treatment of two groups were compared. Result： The total effective rate of the observation group was 90.24%， which was significantly higher than 65.85% of the control group， the difference was statistically significant （Plt;0.05）. There were no significant differences in main renal artery blood flow indexes and renal function indexes between the two groups before treatment （Pgt;0.05）; after 12 weeks of treatment， the Vps and Ved of the main renal artery in the two groups were higher than those before treatment， and the above indexes in the observation group were significantly higher than those in the control group， the RI in the two groups was lower than that before treatment， and the RI in the observation group was lower than that in the control group; the Cr， 24 h urine protein， BUN and UAER of the two groups were significantly lower than those before treatment， and the observation group was significantly lower than the control group， the GFR of the two groups were higher than those before treatment， and the observation group was higher than the control group， the differences were statistically significant （Plt;0.05）. Conclusion： The effect of Piperazine Ferulate combined with Irbesartan in the patients with diabetic nephropathy is better， and can effectively improve kidney function， so its application value in the patients with diabetic nephropathy is relatively higher.

[Key words] Piperazine Ferulate Irbesartan Diabetic nephropathy Kidney function

First-author's address： The Second People's Hospital of Jingdezhen， Jiangxi Province， Jingdezhen 333000， China

doi：10.3969/j.issn.1674-4985.2023.31.004

糖尿病腎病（diabetic nephropathy，DN）是糖尿病的常見嚴重并發癥，可導致患者出現尿白蛋白及腎功能的下降等情況，嚴重影響到患者健康狀態[1-2]。對于DN的研究顯示，本類患者腎血流狀態相對較差，對其進行治療過程中，腎血流改善需求較高[3]。……